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Abstract: Headspace-solid phase microextraction gas chromatography-mass spectrometry
(HS-SPME-GC-MS) can be used to measure volatile organic compounds (VOCs) in human urine.
However, there is no widely adopted standardised protocol for the preparation of urine samples
for analysis resulting in an inability to compare studies reliably between laboratories. This paper
investigated the effect of altering urine sample pH, volume, and vial size for optimising detection of
VOCs when using HS-SPME-GC-MS. This is the first, direct comparison of H2SO4, HCl, and NaOH
as treatment techniques prior to HS-SPME-GC-MS analysis. Altering urine sample pH indicates
that H2SO4 is more effective at optimising detection of VOCs than HCl or NaOH. H2SO4 resulted
in a significantly larger mean number of VOCs being identified per sample (on average, 33.5 VOCs
to 24.3 in HCl or 12.2 in NaOH treated urine) and more unique VOCs, produced a more diverse
range of classes of VOCs, and led to less HS-SPME-GC-MS degradation. We propose that adding
0.2 mL of 2.5 M H2SO4 to 1 mL of urine within a 10 mL headspace vial is the optimal sample
preparation prior to HS-SPME-GC-MS analysis. We hope the use of our optimised method for urinary
HS-SPME-GC-MS analysis will enhance our understanding of human disease and bolster metabolic
biomarker identification.
Keywords: volatile organic compounds; VOCs; H2SO4; NaOH; HCl; sodium hydroxide; hydrochloric
acid; HS-SPME-GC-MS; vials
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1. Introduction
1.1. Metabolomics and Volatile Organic Compounds
Metabolomics identifies de novo or changing metabolites, often in the form of volatile
organic compounds (VOCs) from biological samples [1]. In the 1970s, Horning et al. used gas
chromatography-mass spectrometry (GC-MS) to measure VOCs in human urine and tissues for the
first time [2]. Since then, the study of VOCs has grown exponentially [3,4]. However, there is no
widely adopted standardised protocol for the preparation of urine samples for analysis resulting in an
inability to compare studies reliably between laboratories [5,6].
VOCs usually have fewer than 12 carbon atoms, a boiling point of less than 300 ◦C, and are
biological or synthetic in origin [3,5–7]. They have a high vapour pressure and low molecular weight
enabling them to enter the gas phase at ambient temperatures; they may have an odour and emanate
from urine, faeces, saliva, breath, and other bodily products [5,8]. VOCs are produced by a variety
of processes including degradation from metabolic pathway intermediates, and, therefore, their
concentration in samples can give an insight into biochemical activity upstream, with potential to be
biomarkers of disease [2,6].
So far, VOC analysis of faeces has shown: (i) the increase in esters of short chain fatty acids,
cyclohexanecarboxylic acid and its ester derivatives associated with inflammatory bowel syndrome
(diarrhoea type) [9]; (ii) the loss of short chain fatty acid in active inflammatory bowel disease [10,11]
and, finally, (iii) an increase in propan-2-ol and the ratio of propan-2-ol to 3-methylbutanoic acid
in colorectal cancer [12]. Urinary VOCs have unsurprisingly been proposed to be useful to detect
metabolic changes in conditions involved in urological systems, for example, urinary tract infection [13],
minimal change type nephrotic syndrome [14], and urological cancer detection (kidney, renal cell
carcinoma, and bladder) [1,15–17]. Moreover, urinary VOCs have also been proposed for the detection
of a wide range of other cancers outside the urological systems [18,19], including colorectal cancer [20],
head and neck cancer [21], and lung cancer [22]).
Regarding the classes of VOCs detected in biological materials, De Lacy Costello et al. reviewed
VOCs present in different biological materials and found that the proportion of compound classes
varied between biological materials. Urine contained a high number of ketones, furans, and ethers and
almost no ester compounds [23]. More recently, a review on lung cancer urinary VOCs suggested that
ketones, aldehydes, and ethyl acetate could be useful in detecting lung cancer patients [22]. Excitingly,
the use of VOCs for diagnosis is still in its infancy.
1.2. Analysis of Volatile Organic Compounds
Detection of VOCs requires precise, reliable, and effective instrumentation [23–27]. One of
the more popular techniques is headspace-solid phase microextraction coupled with GC-MS
(HS-SPME-GC-MS) [4,7,8,23,28]. It is a fast and cost-efficient technique that has identified substantial
numbers of VOCs in biological material from both humans and other species [5]. HS-SPME-GC-MS
delivers an exceptional combination of metabolite selectivity and specificity [29]. The solid phase
microextraction (SPME) fibre adsorbs VOCs in the headspace of a sample—improving on GC-MS
alone. It provides a small, low-cost, and solvent-free pre-concentration technology which simplifies
sample preparation into one step [6,8,30].
1.3. Why Urine?
A variety of biofluids are amenable to VOC analysis by HS-SPME-GC-MS; however, urine is ideal
as it can be sampled frequently, easily, non-invasively, and stored for long periods [31]. Additionally,
urine samples generate an intricate and comprehensive metabolomic profile, with VOCs ranging in
polarity and complexity [4]. The added benefit of using urine is that it contains end-products from
multiple metabolic processes, unlike faeces which predominantly represents the alterations in the
gut. Breath is a potential alternative to urine, as it is easy to collect and represents a ‘filtrate’ of blood
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passing though the lungs. However, breath is difficult to store and the concentrations of VOCS are
low [32–34]. Urine appears to be an ideal biofluid for biomarker screening, clinical diagnoses, and the
monitoring of treatment [1,21,25,35–37].
1.4. Sample Preparation
Different sample preparation methods optimise VOC detection including adding salt, acid or base
to the sample [2,6–8,38]; freeze-drying (removing water from a sample while keeping it frozen) [6];
and altering phase ratio (the ratio between sample volume and gas volume in a vial), by changing the
volume of the vial or the urine sample [6,7,39]. Acidified treatment techniques produce more VOCs
than neutral pH and the Divinylbenzene/Carboxen/Polydimethylsiloxane (DVB/CAR/PDMS) SPME
fibre enhances analytic performance more than other types of SPME fibres [5,39]. However, the current
evidence base is small. The above methods change the ionic strength, polarity or solubility of the
samples resulting in a higher concentration of VOCs in the gaseous phase.
Sulphuric acid as a sample preparation treatment technique has rarely been explored and
information altering phase ratio is inconclusive [5,8,40].
This paper investigates the effect of altering urine sample volume, vial size, and pH for optimising
detection of VOCs when using HS-SPME-GC-MS.
2. Results
2.1. Altering Urine Sample pH by the Addition of 5 M H2SO4, 5 M HCl, or 5 M NaOH
2.1.1. Number of VOCs
Urine samples’ (1 mL) pH was altered by the addition of 0.2 mL 5 M H2SO4, 5 M HCl, or 5 M
NaOH (to generate sample solutions of 0.83 M, pH 0.075, pH 0.081, and pH 13.919, respectively). The
mean number of VOCs per sample for each treatment technique (±standard deviation (SD), coefficient
of variation (CV)) were 33.5 (±10.3, 30.7%), 24.3 (±9.6, 39.5%), and 12.2 (±3.0, 24.6%) in H2SO4, HCl,
and NaOH, respectively; all differences were significant (p < 0.01; Wilcoxon signed-rank test) (n = 26)
(Figure 1A). There were 73 unique VOCs in the H2SO4 treatment group compared to 16 in NaOH
(Figure 1B). Evaluating the 31 VOCs shared between the H2SO4 and NaOH treated samples, three VOCs
in H2SO4 (2-buta-1,3-dienyl-1,3,5-trimethylbenzene, methyldisulfanylmethane, and hexanal) and two
VOCs (heptan-2-one and pentan-2-one) in NaOH had significantly greater abundances compared to
their counterparts (p < 0.05, respectively; FC > 1.5, FC < −1.5). There were 27 unique VOCs in the
H2SO4 treatment group compared to four in HCl (Figure 1C). Evaluating the 77 VOCs shared between
both H2SO4 treatment and HCl treatment groups, no compounds had a significantly greater abundance
compared to their counterpart (p < 0.05, respectively; FC > 1.5, FC < −1.5).
2.1.2. Classification of VOCs
5 M H2SO4, 5 M HCl, and 5 M NaOH treatment groups (sample solutions of 0.83 M; pH 0.075,
pH 0.081, and pH 13.919, respectively) had a total of 18, 16, and 15 different compound classes.
The 5 M H2SO4 treatment group (0.83 M final concentration, pH 0.075) produced more classes of
VOCs than 5 M NaOH (0.83 M final concentration, pH 13.919) (Figure 1D). H2SO4 treatment identified
a higher average number of VOCs classified as aldehyde, alkaloid, azetidine, benzene derivative,
carboxylic acid, cosmetic, cycloparaffin, furan, sulphur compound, terpene or unclassified; while it
identified a lower average number of VOCs classified as alcohol, alkane, amine, azole, contaminant,
ketone, tetrazine, therapeutic, and unknown. Compared to HCl (pH 0.081), the H2SO4 (pH 0.075)
treatment group resulted in a higher average number of VOCs classified as aldehyde, alkaloid, azole,
carboxylic acid, furan, ketone, and sulphur compounds; while it identified a lower average number of
VOCs classified as alcohol, amine, azetidine, benzene derivative, contaminant, cosmetic, cycloparaffin,
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terpene, tetrazine, unclassified, and unknown (Figure 1D). The full breakdown of classification of
VOCs can be found in Supplementary Table S3, and per treatment group in Supplementary Table S4.Metabolites 2020, 10, x 4 of 17 
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2.1.3. HS-SPME-GC-MS Degradation
The H2SO4 treatment group (sample solutions of 0.83 M, pH 0.075) was associated with less
degradation than with either 5 M HCl (sample solutions of 0.83 M, pH 0.081) or 5 M NaOH (sample
solutions of 0.83 M, pH 13.919). There were five compounds of degradation that were more abundant
with HCl than H2SO4 and just one that was more common with H2SO4 (p < 0.01, respectively;
Wilcoxon-signed rank test). NaOH was associated with five degradation compounds that were
significantly more abundant than compared to H2SO4 (p < 0.01, respectively; Wilcoxon-signed rank
test) (Figure 2, Table 1). These degradation products could be coming from either column degradation,
the fibre, vial lid or the septa of the GC inlet.
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Figure 2. Headspace-solid phase microextraction gas chromatography-mass spectrometry
(HS-SPME-GC-MS) degradation across 5 M H2SO4 (red), 5 M HCl (green), and 5 M NaOH (blue)
treatment techniques (to generate sample solutions of 0.83 M; pH 0.075, pH 0.081, and pH 13.919,
respectively). Box plots show the abundances of identified contaminants per treatment technique.
Compounds of degradation are based on their retention times.
Table 1. HS-SPME-GC-MS degradation relating retention time to its IUPAC name.
Retention Time
(min) Compound Name (IUPAC Name) H2SO4 v HCl
1 H2SO4 v NaOH 1
16.53 dihydroxy(dimethyl)silane - <0.01
16.93 2,2,4,4,6,6-hexamethyl-1,3,5,2,4,6-trioxatrisilinane <0.01 >0.01
23.1 2,2,4,4,6,6,8,8-octamethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane <0.01 >0.01
24.03 [(dimethyl-3-silanyl)oxy-dimeth silyl]oxy-dimethylsilicon <0.01 -
24.3 trimethoxy(methyl)silane - -
28.51 2-Hydroxymandelic acid, ethyl ester, di-TMS >0.01 >0.01
28.51_2 2,4-bis(trimethylsilyloxy)benzaldehyde <0.01 <0.01
28.53 Tetramet ylsilane <0.01 <0.01
29.28 2,2,4,4,6,6-hexamethyl-1,3,5,2,4,6-trioxatrisilinane - <0.01
33.87 Tetramethylsilane >0.01 >0.01
36.56 trimethyl(1-tri ethylsilylethyl)silane >0.01 -
38.75 bis[[dimethyl(trimethylsilyloxy)silyl]oxy]-dimethylsilane <0.01 <0.01
1 Wilcoxon-signed rank test (p-v lue).
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2.1.4. Conclusion on Altering Sample pH
Overall, altering sample pH using H2SO4 (final concentration 0.83 M, pH 0.075) resulted in more
VOCs being detected than following either of the other treatments. H2SO4 treatment resulted in a
significantly larger mean number of VOCs per sample and more unique VOCs, produced more VOCs
with significantly greater abundances than their counterparts, produced a more diverse range of classes
of VOCs, and led to less HS-SPME-GC-MS degradation products being detected.
2.2. Altering Concentration of H2SO4
The mean (±SD, CV) numbers of VOCs per sample resuspended with 5 M, 2.5 M, and 1 M H2SO4
(to generate sample solutions of 0.83 M, 0.42 M, and 0.17 M, respectively, pH 0.075, pH 0.365, and
pH 0.743, respectively) were 30.3 (±6.5, 21.5%), 24.2 (±6.7, 27.7%), and 16.1 (±7.9, 49.1%), respectively
(n = 15). The 1 M concentration has a significantly lower mean number of VOCs than 2.5 M and 5 M
treated samples, respectively (p < 0.05 and p < 0.01; Wilcoxon signed-rank test); however, there was no
statistically significant difference in the mean number of VOCs between 2.5 M and 5 M concentrations.
There were 4 unique VOCs in the 2.5 M concentration compared to 12 VOCs in 5 M (Figure 3).
Evaluation of the 71 VOCs found commonly when samples are resuspended in either concentration of
H2SO4 showed no significant differences in the abundances of VOCs produced (p < 0.05; FC > 1.5,
FC < −1.5).
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2.3. Altering Phase Ratio of H2SO4 Treated Urine Samples via Altering Vial Volume and Volume of Urine
2.3.1. The Vial Size
The mean (±SD, CV) numbers of VOCs per 0.5 mL sample (treated with 0.1 mL 5 M H2SO4, to yield
0.83 M final solution, pH 0.075) for each vial size were 20.8 (±9.3, 44.7%) and 27.6 (±9.7, 35.1%) in 2 mL
and 10 mL vials, respectively; the difference was significant (p < 0.01; Wilcoxon signed-rank test) (n = 15).
There were 14 unique VOCs in the 10 mL vial compared to 3 in the 2 mL vial (Figure 4). Evaluating the
62 VOCs shared between the vial sizes showed that one VOC ((methyldisulfanyl)methane) in the 2 mL
had a significantly greater abundance compared to its counterpart (p < 0.05; FC > 1.5, FC < −1.5).
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3. Discussion 
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2.3.2. The Volume of Urine
The mean (±SD, RSD/CV) numbers of VOCs per sample for each volume of urine (treated with
5 M H2SO4, to yield 0.83 M final solution, pH 0.075) were 30.5 (±10.5, 34.4%) and 27.6 (±9.7, 35.1%) in
1 mL and 0.5 mL of urine, respectively; the difference was significant (p < 0.01; Wilcoxon signed-rank
test) (n = 15). There were 17 unique VOCs in the 1 mL urine sample compared to six VOCs in the
0.5 mL urine sample (Figure 5). Evaluating the 70 VOCs shared between volume of urine samples,
showed no significant differences in the abundances of VOCs produced (p < 0.05; FC > 1.5, FC < −1.5).
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of unique VOCs produced p r sample for ither volume of urine. (b) V nn diagram showing t e unique
VOCs detected in ach volume of urine.
3. Discussion
HS-SPME-GC-MS analysis of urine offers the potential for fast, non-invasive metabolite detection
but standardisation of methods between laboratories remains a challenge. We have shown that altering
urine sample pH vi the addition of H2SO4 is more effective at optimising detection of VOCs tha
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NaOH or HCl. Ionic strength due to the addition of saturated NaCl solution was also examined in
pooled QC samples and sample urine. We found less compounds were detected when using saturated
NaCl compared to any other method of preparation (Figure S1). H2SO4 resulted in a significantly
larger mean number of VOCs identified per sample and more unique VOCs, produced a more diverse
range of classes of VOCs, and led to less HS-SPME-GC-MS degradation. In addition, we found that
resuspension of samples with 2.5 M and 5 M H2SO4 yielded significantly better detection of VOCs
compared to 1 M acid. Furthermore, using a 10 mL vial and 2.5 M or 5 M H2SO4 further optimised
VOC detection.
Different urine sample treatment techniques alter the sample matrix. Firstly, change in pH may
lead to an increase in decomposition or degradation of certain compounds present in the sample.
In particular, using strong oxidizing acid will almost certainly change the sample composition. Secondly,
changing either the ionic strength or pH may increase activity coefficients (how much a solution differs
from an ideal solution), in turn, decreasing the partition coefficients (the ratio of the concentration
of a sample in the liquid phase with the concentration of VOCs in the headspace), and, ultimately,
resulting in more compounds transitioning into the gas phase. It known that an acid environment
leads to a larger number of VOCs produced compared with a neutral or alkaline environment [6,38].
Despite this, there is a lack of consistency in the approaches described in the literature with either acid,
alkali, and/or salts used as a sample treatment [2,8,16,31,41–46].
When acidification is chosen for HS-SPME-GC-MS, HCl appears to be the most common choice;
although, the reason for this is typically not explained. We found here that HCl produced more
degradation products than H2SO4. Neither HCl nor H2SO4 is very volatile and therefore they can
accumulate at the front of the column. If they remain there, they will damage the stationary phase of
the HS-SPME-GC-MS resulting in premature and excessive column bleed, reflected by an increased
detection of degradation products. Both acids may lead to some deterioration of the SPME fibre; this
requires further study. HCl is a stronger acid than H2SO4, which may explain the greater number of
compounds of degradation. Furthermore, samples resuspended with HCl yielded a lower number of
VOCs than H2SO4 from our urine samples. Notably, the only other paper that has described the use of
H2SO4 as a urine sample treatment technique for HS-SPME-GC-MS analysis, did not compare different
acidification techniques for optimising urinary VOCs in HS-SPME-GC-MS [8]. After establishing
H2SO4 as the most effective treatment technique, we conducted further experiments altering other
aspects of sample preparation, such as H2SO4 concentration and phase ratio.
A higher concentration of acid will lead to a greater increase in the activity coefficients, resulting in
a larger concentration of compounds in the headspace. Previously, 1 M H2SO4 has been used; however,
we found that both 2.5 M and 5 M H2SO4 were significantly more effective at producing VOCs detected
using our HS-SPME-GC-MS method [8]. There was no significant difference in the number of VOCs
produced between 5 M and 2.5 M H2SO4; the reason for this is likely to be that the SPME fibre is
saturated with VOCs at 2.5 M, and, thus, there was no difference when using a higher concentration [5].
We anticipate using a more concentrated acid may lead to more extensive damage to the column or
SPME fibre, leading to further contamination of the samples. Future studies evaluating the effects
of changing the volume of acid used at the same concentration would be beneficial. A recent report
recommended the use of 1 M H2SO4 for the optimisation of liquid-liquid extraction (LLE) coupled
with GC-MS. This is an alternative to SPME but it is more tedious, time-consuming, and requires larger
volumes of solvents [47–49].
Over the course of our study the repeated use of pooled urine QC samples at regular intervals
indicated that there was no significant problem with volatile compound detection, suggesting adsorption
was not being decreased over this period of time (Figure 6). Further, looking at the three most abundant
compounds over time in a larger experiment using 5 M H2SO4, over a period of 15 days, where we ran
over 200 samples, indicated that there was no change to detection over this time period (Figure S2).
As sulphuric acid is a strong oxidizing acid, its use will lead to the formation of sulphates, and whether
these enter the gas phase and lead to fibre damage requires further study. Future studies should
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also include a study of the long-term stability of the fibre under acidic conditions. This study would
physically measure the fibre and continue to use pooled QC samples in order to show that the fibre
was intact and continuing to adsorb efficiently. This study would indicate the optimal time to change
the fibre. These further studies on SPME fibre degradation are vital, since SPME fibres have a high cost
associated with them. It is therefore important to consider how many samples can be run per fibre to
make this a viable avenue moving forward.
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Aggio et al. suggest freeze-drying as an effective alternative to simple treatment techniques,
but it is not applicable to everyone because of limited access to freeze-driers and the long sample
preparation time (up to 17 h) [6]. Simple treatment techniques, such as the addition of acids, require
little training and are extremely easy. Moreover, Aggio et al. found freeze-drying to be comparable to
HCl [6], whereas we have found H2SO4 to be significantly better than HCl. The ability to maximise the
number and quality of VOCs produced from a sample will offer significant advantages to the field
of metabolomics.
Future work will involve the application of this optimised method for the use in HS-SPME-GC-MS
analysis to enhance our understanding of human disease and identify novel diagnostic markers
of disease.
4. Materials and Methods
4.1. Donor Recruitment and Ethical Consent
49 donors were recruited. Regulatory approval was granted by North Wales Research Ethics
Committee–West (REC reference 15/WA/0464, REC name: Wales REC 5, Date of REC opinion: 21
December 2015). Written informed consent was obtained prior to recruitment.
4.2. Urine Samples
5 mL of urine was collected from each donor and frozen at −20 ◦C for storage. The collected urine
was thawed at room temperature for 1–3 h, vortexed, and then divided into 1 mL aliquots contained
within 10 mL vials. The new 1 mL urine aliquots were then refrozen and stored at −20 ◦C prior to
sample preparation.
4.3. Chemicals and Materials
5 M sulphuric acid solution (H2SO4) and 5 M hydrochloric acid solution (HCl) were purchased
from Fisher Scientific (Loughborough, UK). 5 M sodium hydroxide (NaOH) solution was obtained
from Sigma Aldrich (Dorset, UK). The 10 mL vials (screw top, rounded bottom, clear glass vial) and
caps (screw cap, magnetic, PTFE/silicone septum, septum thickness 1.3 mm) were also from Sigma
Aldrich. The 2 mL vials (crimp top, clear. Vial size: 12 × 32 mm (11 mm cap)) and caps (crimp
steel gold, magnetic, white silicone/PTFE septa, 11 mm) were purchased from Agilent Technologies
(Cheshire, UK).
4.4. Experimental Conditions
We defrosted samples at room temperature prior to sample preparation. The following sample
preparation experiments were performed:
4.4.1. Altering Sample pH (and Ionic Strength)
Twenty-six triplicate urine samples of 1 mL were combined with 0.2 mL of 5 M H2SO4, 5 M HCl or
5 M NaOH (or saturated NaCl solution). The resulting concentration of H2SO4, HCl or NaOH treated
urine sample solution was 0.83 M, pH 0.075, pH 0.081, and pH 13.919, respectively.
4.4.2. Altering Concentration of H2SO4
Fifteen duplicate urine samples of 1 mL were combined with 0.2 mL of 5 M H2SO4, 2.5 M H2SO4
or 1 M H2SO4. The resulting concentrations of the urine sample solutions were 0.83 M, 0.42 M or
0.17 M respectively pH 0.075, pH 0.365, and pH 0.743, respectively.
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4.4.3. Altering Phase Ratio by Changing Vial Size
Fifteen duplicate urine samples of 1 mL were aliquoted into 0.5 mL urine samples and separated
into 2 mL or 10 mL vials, respectively, and were combined with 0.1 mL of 5 M H2SO4 solution. The
resulting concentration of each urine sample solution was 0.83 M, pH 0.075.
4.4.4. Altering Phase Ratio by Changing the Sample Volume
Fifteen duplicate urine samples of 1 mL were chosen. One set of duplicates was treated with
0.2 mL of 5 M H2SO4 solution. The other set had 0.5 mL of urine aliquoted in a 10 mL vial with 0.1 mL
5 M H2SO4 solution. The resulting concentration of each urine sample solution was 0.83 M, pH 0.075.
All samples were vortexed for 10 s prior to analysis.
4.5. Static Headspace-SPME-GC-MS Analysis
A Perkin Elmer Clarus 500 GC-MS quadruple bench top system (Beaconsfield, UK) was used
in combination with a Combi PAL PAL COMBI-xt autosampler (CTC Analytics, Switzerland, https:
//www.palsystem.com/). The GC column used was a Zebron ZB-624 with inner diameter 0.25 mm,
length 60 m, and film thickness 1.4 µm (Phenomenex, Macclesfield, UK). The carrier gas used was
helium of 99.996% purity (BOC, Sheffield, UK). A DVB/CAR/PDMS SPME fibre (needle size 23 ga,
StableFlex, for use with autosampler) was obtained from Sigma-Aldrich (#57298U) and pre-conditioned
before use, as per manufacturer’s instructions, 4 × 30 min heating at 300 ◦C. A blank was always then
run to check the fibre was clean before use.
Urine samples were placed in a Combi PAL PAL COMBI-xt autosampler (CTC Analytics,
Switzerland, https://www.palsystem.com/) incubation chamber at 60 ◦C for 30 min, followed by the
extraction of volatiles from the headspace of the vial and adsorption to the SPME fibre for 20 min (static
HS-SPME). The fibre was then inserted into the GC component for desorption at 220 ◦C for 5 min.
The initial temperature of the GC oven was set at 40 ◦C, held for 2 min, increased to 220 ◦C at a rate of
5 ◦C/min and then held for 4 min, with a total run time of 42 min. A solvent delay was set for the first
4 min and the MS was operated in positive electron impact ionization EI+ mode, scanning from ion
mass fragments 10–300 m/z, with an interscan delay of 0.1 s and a resolution of 1000 at FWHM (Full
Width at Half Maximum). The helium gas flow rate was set at 1 mL/min. All samples were randomly
ordered (using Microsoft Excel’s = RAND() function) and injected, essentially as described previously
by Aggio et al. [6].
4.6. Library Building
After HS-SPME-GC-MS, chromatograms were generated (Figure 7, Table 2). Individual peaks
were analysed by Automated Mass Spectral Deconvolution and Identification System (AMDIS, version
2.71, 2012, AMDIS is a freely available and sophisticated software for GC-MS data interpretation from
NIST www.amdis.net) software, in conjunction with the National Institute of Standards and Technology
mass spectral library (NIST, version 17, 2019, Purchased from SS Scientific Limited, Eastbourne, UK).
Peaks were added to a local library: if they had a forward match of greater than 740/1000, they were
silica based degradation products (5 compounds), if they had a good shape total ion count trace (2
unknown compounds), or if they had previously been identified in other studies in our lab. The final
local library contained 173 unique VOCs (Table S1).
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Figure 7. Example of typical chromatograms of duplicate 1 mL urine samples generated from
HS-SPME-GC-MS following treatment with 0.2 mL of 5 M H2SO4 (red) or 5 M NaOH (blue). The 13
most abundant chemicals in urine treated with 5 M H2SO4 and nine most abundant chemicals in urine
treated with 5 M NaOH are labelled and further information regarding these peaks can be seen in
Table 2.
Table 2. Most abundant chemicals in chromatogram.
Label Retention Time(min) Compound Name (IUPAC Name)
1 16.93 2,2,4,4,6,6-hexamethyl-1,3,5,2,4,6-trioxatrisilinane (Contaminant) *
2 20.88 heptan-4-one *
3 21.44 heptan-3-one *
4 24.67 2-methyl-5-methylsulfanylfuran
5 26.01 1-methyl-4-propan-2-ylbenzen (p-Cimen )
6 26.93 2-ethylhexan-1-ol *
7 27.76 Phenol
8 28.55 1-methyl-4-prop-1-en-2-ylbenzene-or-1-methyl-2-prop-1-en-2-ylbenzene
9 30.61 4-methylphenol
10 31.83 (1R,2R,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol
11 32.14 5-methyl-2-propan-2-ylcyclohexan-1-ol(Menthol)
12 35.42 3-methyl-6-propan-2-ylcyclohex-2-en-1-one *
13 37.32 2-buta-1,3-dienyl-1,3,5-trimethylbenzene
14 16.93 2,2,4,4,6,6-hexamethyl-1,3,5,2,4,6-trioxatrisilinane (Contaminant) *
15 20.88 heptan-4-one *
16 21.44 heptan-3-one *
17 21.71 heptan-2-one
18 22.61 (E)-2-methylhept-2-enal
19 23.10 2,2,4,4,6,6,8,8-octamethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane (Contaminant) *
20 23.91 Oxime-, methoxy-phenyl-(Contaminant)
21 26.93 2-ethylhexan-1-ol *
22 28.53 Tetramethylsilane (TMS) (Contaminant)
23 35.42 3-methyl-6-propan-2-ylcyclohex-2-en-1-one *
* Some compounds appear in this table twice as they are highly abundant in both treatment conditions.
A batch report was generated from AMDIS using the local library with deconvolution settings as
follows: component width of 10, adjacent peak subtraction of one, low resolution, low sensitivity, and
low shape requirements. Freely available R package Metab (Bioconductor) was used to generate a
spreadsheet of VOCs per sample, using a half a minute time-window [55]. Contaminants identified with
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system suitability tests were removed before statistical analysis as described above. Statistics and figures
were produced using Excel, the freely-available MetaboAnalyst website (McGill University, Canada,
Xia Lab, https://www.metaboanalyst.ca/), or free software environment for statistical computing and
graphics R software [56,57].
Data was normalized by median, transformed logarithmically, and auto scaled accordingly
to ensure that all metabolites were given equal weight during the analysis and to increase the
interpretability of the models produced.
4.7. System Suitability and Quality Control
A set of QC samples was produced by pooling 1 mL from 50 urine samples (including urine
samples used in this paper) and aliquoting this into 1 mL samples. These acted as technical replicates
run with each batch of study samples to provide a reference to indicate temporal stability measure
HS-SPME-GC-MS. Parts of the SPME fibre or stationary phase of the GC column contain polysiloxanes
that can degrade to produce volatile siloxanes [6]. Therefore, before every batch of sample processing,
a “laboratory air” (uncapped, empty vial) was run, such that the SPME fibre sampled the air for
20 min at room temperature. We ran “blank” samples (capped, empty vials) after every 8 study
samples. Compounds appearing in either laboratory air or blank samples revealed impurities and were
considered contaminants if they were present in >50% of controls and blanks. These were removed
from statistical analysis to ensure that analysed VOCs originated from individual urine samples being
tested and prevented carry-over of VOCs on the SPME fibre between samples [5]. Collectively, QC,
blanks, and laboratory air samples made up a set of system suitability samples, that were processed
under the same experimental conditions as ‘real’ samples, and assured analytic metrics were “fit for
purpose” [52].
4.8. Equipment Stability of the HS-SPME-GC-MS Over Time
We assessed the clustering of QC samples using principal component analysis (PCA) plots.
Additionally, the coefficient of variation (CV) was calculated per sample per treatment technique for
each compound identified.
The acid treatment techniques, using H2SO4 or HCl, produced tightly clustered QC technical
replicates that reflect the stability of the HS-SPME-GC-MS over the duration of the study. Importantly,
this reflects the stability of the SPME fibre, despite the use of strong, oxidizing acid treatment techniques,
and strengthens the robustness of our study. The technical replicate of NaOH treated urine also
produced tightly clustered data in two distinct groups (Figure 6). As these were QC technical replicates,
the intra-cluster variations must be due to an analytical variation in HS-SPME-GC-MS processing.
Since both NaOH clusters remained within the 95% confidence interval of the study samples, this
indicates the analytic variation was only minor and suggests that the quality of is good. The CV of VOC
peak area was calculated for VOCs shared between QC technical replicates of each treatment technique.
CV values were 0.07–4.33%, 0.15–5.28%, and 0.01–3.81% for H2SO4, HCl, and NaOH, respectively.
Full lists are shown in Supplementary Table S2a–c.
4.9. Compound Identification
Group arithmetic means were compared using a Wilcoxon-signed rank test. The presence of
VOCs in each condition was compared using Venn diagrams generated through R software [58].
Univariate methods were used to measure differences in abundance: fold change (FC > 1.5, FC < −1.5)
and p < 0.05 (false discovery rate [FDR] adjusted) were considered significant. The identified compounds
were then grouped into chemical classes based on the MeSH (Medical Subject Headings) compound
database [59].
Metabolites 2020, 10, 482 14 of 17
4.10. HS-SPME-GC-MS Degradation
In order to identify the detrimental effect of each treatment on the equipment; we compared the
abundance of contaminating metabolites originating from HS-SPME-GC-MS. The Wilcoxon-signed
rank test was used to identify significant differences in HS-SPME-GC-MS degradation.
5. Conclusions
We optimised the detection of VOCs in urine using HS-SPME-GC-MS by altering pH, H2SO4
concentration, and phase ratio. This is the first direct comparison of H2SO4, HCl, and NaOH as
treatment techniques prior to HS-SPME-GC-MS analysis. Altering urine sample pH indicates that
H2SO4 is more effective at optimising detection of VOCs than NaOH or HCl. H2SO4 resulted in
a significantly larger mean number of VOCs being identified per sample and more unique VOCs,
produced more VOCs with significantly greater abundance than their counterparts, produced a more
diverse range of classes of VOCs, and led to less HS-SPME-GC-MS degradation. We propose that
adding 0.2 mL of 2.5 M H2SO4 to 1 mL of urine within a 10 mL headspace vial is the optimal sample
preparation prior to HS-SPME-GC-MS analysis. We hope the use of our optimised method for urinary
HS-SPME-GC-MS analysis will enhance our understanding of human disease and bolster metabolic
biomarker identification.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/12/482/s1,
Figure S1: Number of VOCs detected when altering pH or ionic strength using saturated NaCl solution. Figure S2:
Equipment stability of the HS-SPME-GC-MS over time using 5 M H2SO4. Table S1: The final local library
containing 173 unique VOCs. Please note this is an .MSL file. Table S2a: A full list of CV values for VOCs detected
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